# Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

> **NCT03440567** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Avelumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide Phosphate
- **DRUG:** Ibrutinib
- **DRUG:** Ifosfamide
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Utomilumab

## Key facts

- **NCT ID:** NCT03440567
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-02
- **Primary completion:** 2024-06-26
- **Final completion:** 2024-06-26
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03440567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03440567, "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03440567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*